May 1, 2026 Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
May 1, 2026 Guo Guangchang: Fosun International’s NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas